Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset

Boehringer Ingelheim is handing over a total of 38.8 million euros ($42 million) to long-time partner OSE Immunotherapeutics for a preclinical anti-PD1/cytokine drug as well as to expand their existing solid tumor work into cardio-renal-metabolic diseases.